Arcutis Biotherapeutics
ARQT
50 hedge funds and large institutions have $974M invested in Arcutis Biotherapeutics in 2020 Q1 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
85.81% more ownership
Funds ownership: 0% → 85.81% (+86%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
+$283M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$154M |
| 3 |
O
OrbiMed
New York
|
+$126M |
| 4 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$107M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
+$45.3M |
Top Sellers
ARQT Hedge Fund Activity: Q1 2020 in Review
50 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q1 2020, worth a combined $974M.
Buyers outnumbered sellers: 50 funds opened new ARQT positions and 0 closed out — a net gain of 50 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Frazier Management, opening a new position worth an estimated $283M.
- 50 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q1 2020, up from 0 in Q4 2019.
- Funds reported $974M of Arcutis Biotherapeutics stock for Q1 2020.
- 50 funds opened new Arcutis Biotherapeutics positions in Q1 2020 and 0 closed out, a net change of +50 holders.
- The largest Arcutis Biotherapeutics buyer in Q1 2020 was Frazier Management, an estimated $283M added.
Based on aggregated 13F filings for Q1 2020.